5 results for "Hermann".
#134 Gastrointestinal neuroendocrine tumors: tumor characteristics and long-term clinical outcome in the German NET registry
Introduction: Prognosis of neuroendocrine tumors (NETs) has been difficult to predict due to heterogenous tumor biology, various classification systems, and lack of reliable and recent data due to the rarity of these tumors.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: Dr. Ulrich-Frank Pape
Introduction: We recently identified ISL1 as a marker for pancreatic neuroendocrine neoplasms (P-NENs). ISL1 as well as PDX1, CDX2 and NGN3 are transcription factors (TF) involved in pancreato-duodenal development.
Conference: 8th Annual ENETS Conference (2011)
Presenting Author: Gratiana Hermann
Introduction: The mixed adenoneuroendocrine carcinomas (MANEC, WHO 2010) are neoplasms with heterogeneous morphology, whose mixed nature may be difficult to recognize.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: MD Gratiana Hermann
#990 Prolonged Progression-Free Survival with Extended Cycle Streptozotozin/5-FU Chemotherapy in Patients with Metastatic Pancreatic Neuroendocrine Tumors
Introduction: The treatment of pancreatic neuroendocrine tumors with streptozotocin-based chemotherapy is well-established.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Joerg Schrader
#1118 Is There an Additional Value of Somatostatin Receptor Subtype 2A Immunohistochemistry Over Somatostatin Receptor Scintigraphy in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
Introduction: It is not known whether tumoral somatostatin receptor subtype 2a (sst2a) immunohistochemistry (IHC) has additional value over OctreoScan® uptake in predicting response to PRRT in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: MD Roxanne Van Adrichem